Answer
Tukysa (tucatinib), in combination with trastuzumab and capecitabine, is indicated for adults with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
Sources for this answer
- TUKYSA 50 mg film-coated tabletPfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 5Document updated
Sources checked